Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Effect of PEX, a noncatalytic metalloproteinase fragment with integrin-binding activity, on experimental Chlamydophila pneumoniae infection.
Caronzolo D, Lucini V, Pannacci M, Grosso S, Kieffer N, Bello L, Bikfalvi A, Scaglione F.
Antimicrob Agents Chemother. 2006 Oct;50(10):3277-82.
Similar articles
Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae.
Rothstein NM, Quinn TC, Madico G, Gaydos CA, Lowenstein CJ.
J Infect Dis. 2001 Jan 15;183(2):232-238. Epub 2000 Dec 13.
Glucocorticoids increase in vitro and in vivo activities of antibiotics against Chlamydophila pneumoniae.
Caronzolo D, Lucini V, Pannacci M, Grosso S, Colleoni F, Fraschini F, Scaglione F.
Antimicrob Agents Chemother. 2004 Dec;48(12):4878-81.
Toll-like receptors 2 and 4 do not contribute to clearance of Chlamydophila pneumoniae in mice, but are necessary for the release of monokines.
Mueller M, Postius S, Thimm JG, Gueinzius K, Muehldorfer I, Hermann C.
Immunobiology. 2004;209(8):599-608.
Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.
Gieffers J, Füllgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, Solbach W, Maass M.
Circulation. 2001 Jan 23;103(3):351-6.
Acute Chlamydia pneumoniae reinfection accelerates the development of insulin resistance and diabetes in obese C57BL/6 mice.
Wang C, Gao D, Kaltenboeck B.
J Infect Dis. 2009 Jul 15;200(2):279-87. doi: 10.1086/599796.
A 6 week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein E-deficient mice chronically infected with Chlamydia pneumoniae.
Blessing E, Campbell LA, Rosenfeld ME, Chesebro B, Kuo CC.
J Antimicrob Chemother. 2005 Jun;55(6):1037-40. Epub 2005 Apr 21.
In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model.
Kutlin A, Roblin PM, Hammerschlag MR.
Antimicrob Agents Chemother. 1999 Sep;43(9):2268-72.
Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.
Antimicrob Agents Chemother. 2002 Feb;46(2):409-12.
Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection.
Brandén E, Koyi H, Gnarpe J, Gnarpe H, Tornling G.
Scand J Infect Dis. 2004;36(11-12):811-6.
High prevalence of Chlamydia pneumoniae infection in cyclosporin A-induced post-transplant gingival overgrowth tissue and evidence for the possibility of persistent infection despite short-term treatment with azithromycin.
Worm HC, Wirnsberger GH, Mauric A, Holzer H.
Nephrol Dial Transplant. 2004 Jul;19(7):1890-4. Epub 2004 May 5.
Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model.
J Antimicrob Chemother. 2002 May;49(5):763-7.
Advances in the management of Chlamydia pneumoniae infections.
Hammerschlag MR.
Expert Rev Anti Infect Ther. 2003 Oct;1(3):493-503. Review.
Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model.
Hoffman HL, Klepser ME, Ernst EJ, Petzold CR, Sa'adah LM, Doern GV.
Antimicrob Agents Chemother. 2003 Feb;47(2):739-46.
Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis.
Wolf K, Malinverni R.
Antimicrob Agents Chemother. 1999 Jun;43(6):1491-3.
Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study.
Hillis GS, Pearson CV, Harding SA, Sutherland S, Ludlam CA, Marioni JC, Prescott RJ, Fox KA, Flapan AD.
Am Heart J. 2004 Jul;148(1):72-9.
Corn mint (Mentha arvensis) extract diminishes acute Chlamydia pneumoniae infection in vitro and in vivo.
Salin O, Törmäkangas L, Leinonen M, Saario E, Hagström M, Ketola RA, Saikku P, Vuorela H, Vuorela PM.
J Agric Food Chem. 2011 Dec 28;59(24):12836-42. doi: 10.1021/jf2032473. Epub 2011 Nov 22.
Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model.
Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF.
Circulation. 1998 Feb 24;97(7):633-6.
Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.
Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T.
Circulation. 1999 Mar 30;99(12):1540-7.
Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice.
Bin XX, Wolf K, Schaffner T, Malinverni R.
Antimicrob Agents Chemother. 2000 Jun;44(6):1761-4.
Filters: Manage Filters